Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin
Open Access
- 24 September 2019
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 39 (9)
Abstract
An increased metabolic flux towards Warburg phenotype promotes survival, proliferation and causes therapeutic resistance, in leukemic cells. Hexokinase-II (HK-II) is expressed predominantly in cancer cells, which promotes Warburg metabolic phenotype and protects the cancer cells from drug-induced apoptosis. The HK-II inhibitor 3- Bromopyruvate (3-BP) dissociates HK-II from mitochondrial complex, which leads to enhanced sensitization of leukemic cells to anti-leukemic drugs. In the present study, we analyzed the Warburg characteristics viz. HK-II expression, glucose uptake, endogenous reactive oxygen species (ROS) level of leukemic cell lines K-562 and THP-1 and then investigated if 3-BP can sensitize the leukemic cells K-562 to anti-leukemic drug Daunorubicin (DNR). We found that both K-562 and THP-1 cells have multi-fold high levels of HK-II, glucose uptake and endogenous ROS with respect to normal PBMCs. The combined treatment (CT) of 3-BP and DNR showed synergistic effect on the growth inhibition (GI) of K-562 and THP-1 cells. This growth inhibitory effect was attributed to 3-BP induced S-phase block and DNR induced G2/M block, resulted in reduced proliferation due to CT. Further, CT resulted in low HK-II level in mitochondrial fraction, high intracellular calcium and elevated apoptosis as compared with individual treatment of DNR and 3-BP. Moreover, CT caused enhanced DNA damage and hyperpolarized mitochondria, leading to cell death. Taken together, these results suggest that 3-BP synergises the anticancer effects of DNR in the chronic myeloid leukemic cell K-562, and may act as an effective adjuvant to anti-leukemic chemotherapy.Keywords
This publication has 50 references indexed in Scilit:
- Emerging Metabolic Targets in the Therapy of Hematological MalignanciesBioMed Research International, 2013
- Management of imatinib-resistant patients with chronic myeloid leukemiaTherapeutic Advances in Hematology, 2012
- First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemiaLeukemia, 2012
- DNA Damage Response Is Suppressed by the High Cyclin-dependent Kinase 1 Activity in Mitotic Mammalian CellsJournal of Biological Chemistry, 2011
- Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramingOncogene, 2010
- Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cellsBritish Journal of Pharmacology, 2009
- Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvateBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cellsMolecular Cancer, 2009
- Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemiaLeukemia, 2006
- Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaOncogene, 2006